Benita Salomon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Benita Salomon has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Jonas Halfvarson
Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
5 shared publications Adam Carstens
Department of Internal Medicine, Ersta Hospital, Stockholm, Sweden
4 shared publicationsHans Strid
Centre for Digestive Health, Department of Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden
4 shared publicationsHenrik Hjortswang
Department of Gastroenterology, County Council of Östergötland, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
4 shared publicationsSven Almer
Centre for Digestive Health, Department of Gastroenterology, Dermatovenereology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden
4 shared publicationsAndré Blomberg
Department of Medicine, Geriatrics and Emergency Medicine, Sahlgrenska University Hospital, Östra Hospital, Gothenburg, Sweden
3 shared publications
Latest Publications
- Open Access
Altered Levels of Enteric Glial Cells and Their Associated Pro‐Inflammatory Proteins in Patients With Ulcerative Colitis During Active Disease Compared to Remission and Healthy Controls
Background: Enteric glial cells (EGC) play a crucial role in gut barrier maintenance but their role in ulcerative colitis (UC)‐related inflammation is largely unknown. This study investigated EGC and related proteins in patients with UC in inflamed and non‐inflamed segments during clinically active disease and remission following anti‐inflammatory treatment. Methods: Colorectal biopsies were obtained from inflamed and non‐inflamed segments of 14 patients with UC before and after initiating anti‐inflammatory therapy and achieving clinical and endoscopic remission. Control biopsies were collected from 16 healthy controls (HC). EGC markers: glial fibrillary acidic protein (GFAP + ) and S100 calcium‐binding protein β (S100β + ) were assessed by immunofluorescence. Relative estimates of inflammatory proteins in biopsies were analyzed using Olink technology. The EGC cell line CRL‐2690 was exposed to interleukins (IL)‐4 and IL‐6 at varying concentrations and durations, and analyzed by western blotting. Results: EGC GFAP+ and EGC S100β+ were more abundant in inflamed colonic segments during active UC compared to remission ( p < 0.001) and HC ( p < 0.0001). In non‐inflamed segments, EGC GFAP+ decreased significantly with remission ( p < 0.001), whereas EGC S100β+ remained stable. Interleukin stimulation modulated GFAP expression in vitro, with IL‐6 increasing and IL‐4 decreasing in a dose and time‐dependent manner. EGC‐associated proteins, including cytokines, neurotrophic factors and chemokines were elevated in inflamed segments during active UC, normalizing towards HC levels upon remission. Conclusion: Elevated EGC counts, and associated pro‐inflammatory proteins characterize inflamed mucosa during clinical active UC. These novel findings suggest that EGC may be clinically relevant for identifying novel biomarkers for disease monitoring.
Open AccessAltered Levels of Enteric Glial Cells and Their Associated Pro‐Inflammatory Proteins in Patients With Ulcerative Colitis During Active Disease Compared to Remission and Healthy Controls
Background: Enteric glial cells (EGC) play a crucial role in gut barrier maintenance but their role in ulcerative colitis (UC)‐related inflammation is largely unknown. This study investigated EGC and related proteins in patients with UC in inflamed and non‐inflamed segments during clinically active disease and remission following anti‐inflammatory treatment. Methods: Colorectal biopsies were obtained from inflamed and non‐inflamed segments of 14 patients with UC before and after initiating anti‐inflammatory therapy and achieving clinical and endoscopic remission. Control biopsies were collected from 16 healthy controls (HC). EGC markers: glial fibrillary acidic protein (GFAP + ) and S100 calcium‐binding protein β (S100β + ) were assessed by immunofluorescence. Relative estimates of inflammatory proteins in biopsies were analyzed using Olink technology. The EGC cell line CRL‐2690 was exposed to interleukins (IL)‐4 and IL‐6 at varying concentrations and durations, and analyzed by western blotting. Results: EGC GFAP+ and EGC S100β+ were more abundant in inflamed colonic segments during active UC compared to remission ( p < 0.001) and HC ( p < 0.0001). In non‐inflamed segments, EGC GFAP+ decreased significantly with remission ( p < 0.001), whereas EGC S100β+ remained stable. Interleukin stimulation modulated GFAP expression in vitro, with IL‐6 increasing and IL‐4 decreasing in a dose and time‐dependent manner. EGC‐associated proteins, including cytokines, neurotrophic factors and chemokines were elevated in inflamed segments during active UC, normalizing towards HC levels upon remission. Conclusion: Elevated EGC counts, and associated pro‐inflammatory proteins characterize inflamed mucosa during clinical active UC. These novel findings suggest that EGC may be clinically relevant for identifying novel biomarkers for disease monitoring.
- Open Access
Cohort profile: the Swedish Inception Cohort in inflammatory bowel disease (SIC-IBD)
Purpose There is a need for diagnostic and prognostic biosignatures to improve long-term outcomes in inflammatory bowel disease (IBD). Here, we describe the establishment of the Swedish Inception Cohort in IBD (SIC-IBD) and demonstrate its potential for the identification of such signatures. Participants Patients aged ≥18 years with gastrointestinal symptoms who were referred to the gastroenterology unit due to suspected IBD at eight Swedish hospitals between November 2011 and March 2021 were eligible for inclusion. Findings to date In total, 367 patients with IBD (Crohn’s disease, n=142; ulcerative colitis, n=201; IBD-unclassified, n=24) and 168 symptomatic controls were included. In addition, 59 healthy controls without gastrointestinal symptoms were recruited as a second control group. Biospecimens and clinical data were collected at inclusion and in patients with IBD also during follow-up to 10 years. Levels of faecal calprotectin and high-sensitivity C-reactive protein were higher in patients with IBD compared with symptomatic controls and healthy controls. Preliminary results highlight the potential of serum protein signatures and autoantibodies, as well as results from faecal markers, to differentiate between IBD and symptomatic controls in the cohort. During the first year of follow-up, 37% (53/142) of the patients with Crohn’s disease, 24% (48/201) with ulcerative colitis and 4% (1/24) with IBD-U experienced an aggressive disease course. Future plans We have established an inception cohort enabling ongoing initiatives to collect and generate clinical data and multi-omics datasets. The cohort will allow analyses for translation into candidate biosignatures to support clinical decision-making in IBD. Additionally, the data will provide insights into mechanisms of disease pathogenesis.
Open AccessCohort profile: the Swedish Inception Cohort in inflammatory bowel disease (SIC-IBD)
Purpose There is a need for diagnostic and prognostic biosignatures to improve long-term outcomes in inflammatory bowel disease (IBD). Here, we describe the establishment of the Swedish Inception Cohort in IBD (SIC-IBD) and demonstrate its potential for the identification of such signatures. Participants Patients aged ≥18 years with gastrointestinal symptoms who were referred to the gastroenterology unit due to suspected IBD at eight Swedish hospitals between November 2011 and March 2021 were eligible for inclusion. Findings to date In total, 367 patients with IBD (Crohn’s disease, n=142; ulcerative colitis, n=201; IBD-unclassified, n=24) and 168 symptomatic controls were included. In addition, 59 healthy controls without gastrointestinal symptoms were recruited as a second control group. Biospecimens and clinical data were collected at inclusion and in patients with IBD also during follow-up to 10 years. Levels of faecal calprotectin and high-sensitivity C-reactive protein were higher in patients with IBD compared with symptomatic controls and healthy controls. Preliminary results highlight the potential of serum protein signatures and autoantibodies, as well as results from faecal markers, to differentiate between IBD and symptomatic controls in the cohort. During the first year of follow-up, 37% (53/142) of the patients with Crohn’s disease, 24% (48/201) with ulcerative colitis and 4% (1/24) with IBD-U experienced an aggressive disease course. Future plans We have established an inception cohort enabling ongoing initiatives to collect and generate clinical data and multi-omics datasets. The cohort will allow analyses for translation into candidate biosignatures to support clinical decision-making in IBD. Additionally, the data will provide insights into mechanisms of disease pathogenesis.
- Open Access
- 19 April 2025
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (5)
Anti-integrin αvβ6 IgG antibody as a diagnostic and prognostic marker in ulcerative colitis: A cross-sectional and longitudinal study defining a specific disease phenotype
Background and Aims: The diagnostic and prognostic properties of anti-integrin αvβ6 immunoglobulin G (IgG) autoantibodies in ulcerative colitis (UC) are poorly understood. We aimed to assess the diagnostic performance of anti-integrin αvβ6 autoantibodies and examine their association with disease outcomes. Methods: Serum samples from a Swedish inception cohort of patients with suspected inflammatory bowel disease (IBD, n = 473) were analyzed using an in-house fluorescence enzyme immunoassay based on EliA technology. Findings were validated in a Norwegian population-based inception cohort (n = 570). Diagnostic performance was assessed by calculating the area under the curve (AUC) with 95% confidence intervals and determining sensitivity and specificity. Reclassification was evaluated using the net reclassification index. Results: In the discovery cohort, patients with UC, IBD-unclassified, or colonic Crohn’s disease exhibited higher median autoantibody levels compared to symptomatic and healthy controls. In the validation cohort, the autoantibody demonstrated 79% sensitivity and 94% specificity for UC vs symptomatic controls at a cut-off of 400 UA/l. Its diagnostic performance (AUC = 0.92, 95% CI, 0.89-0.95) was superior to hs-CRP (AUC = 0.65, 95% CI, 0.60-0.70, P < .001) and faecal calprotectin (fcalpro) (AUC = 0.88, 95% CI, 0.84-0.92, P = .09). Combining the autoantibody with fcalpro further improved diagnostic accuracy (AUC = 0.97, 95% CI, 0.95-0.98) and patient reclassification (P < .001). Autoantibody positivity was associated with a severe phenotype of UC, characterised by increased inflammatory activity and higher IL-17A and granzyme B levels. Higher autoantibody levels were linked to an aggressive disease course, remaining stable in aggressive UC but decreasing in indolent disease (P = .003). Conclusions: Anti-integrin αvβ6 is a reliable diagnostic and prognostic marker for UC, with potential clinical implementation.
- 19 April 2025
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (5)
Open AccessAnti-integrin αvβ6 IgG antibody as a diagnostic and prognostic marker in ulcerative colitis: A cross-sectional and longitudinal study defining a specific disease phenotype
Background and Aims: The diagnostic and prognostic properties of anti-integrin αvβ6 immunoglobulin G (IgG) autoantibodies in ulcerative colitis (UC) are poorly understood. We aimed to assess the diagnostic performance of anti-integrin αvβ6 autoantibodies and examine their association with disease outcomes. Methods: Serum samples from a Swedish inception cohort of patients with suspected inflammatory bowel disease (IBD, n = 473) were analyzed using an in-house fluorescence enzyme immunoassay based on EliA technology. Findings were validated in a Norwegian population-based inception cohort (n = 570). Diagnostic performance was assessed by calculating the area under the curve (AUC) with 95% confidence intervals and determining sensitivity and specificity. Reclassification was evaluated using the net reclassification index. Results: In the discovery cohort, patients with UC, IBD-unclassified, or colonic Crohn’s disease exhibited higher median autoantibody levels compared to symptomatic and healthy controls. In the validation cohort, the autoantibody demonstrated 79% sensitivity and 94% specificity for UC vs symptomatic controls at a cut-off of 400 UA/l. Its diagnostic performance (AUC = 0.92, 95% CI, 0.89-0.95) was superior to hs-CRP (AUC = 0.65, 95% CI, 0.60-0.70, P < .001) and faecal calprotectin (fcalpro) (AUC = 0.88, 95% CI, 0.84-0.92, P = .09). Combining the autoantibody with fcalpro further improved diagnostic accuracy (AUC = 0.97, 95% CI, 0.95-0.98) and patient reclassification (P < .001). Autoantibody positivity was associated with a severe phenotype of UC, characterised by increased inflammatory activity and higher IL-17A and granzyme B levels. Higher autoantibody levels were linked to an aggressive disease course, remaining stable in aggressive UC but decreasing in indolent disease (P = .003). Conclusions: Anti-integrin αvβ6 is a reliable diagnostic and prognostic marker for UC, with potential clinical implementation.
- Open Access
Cohort profile: The Swedish Inception Cohort in inflammatory bowel disease (SIC-IBD)
Purpose: There is a need for diagnostic and prognostic biosignatures to improve long-term outcomes in inflammatory bowel disease (IBD). Here, we describe the establishment of the Swedish inception cohort in IBD (SIC-IBD) and demonstrate its potential for the identification of such signatures. Participants: Patients aged ≥18 years with gastrointestinal symptoms who were referred to the gastroenterology unit due to suspected IBD at eight Swedish hospitals between November 2011 and March 2021 were eligible for inclusion. Findings to date: In total, 368 patients with IBD (Crohn’s disease, n=143; ulcerative colitis, n=201; IBD-unclassified, n=24) and 168 symptomatic controls were included. In addition, 59 healthy controls without gastrointestinal symptoms were recruited as a second control group. Biospecimens and clinical data were collected at inclusion and in patients with IBD also during follow-up to 10 years. Levels of faecal calprotectin and high-sensitivity C-reactive protein were higher in patients with IBD compared to symptomatic controls and healthy controls. Preliminary results highlight the potential of serum protein signatures and autoantibodies, as well as results from faecal markers, to differentiate between IBD and symptomatic controls in the cohort. During the first year of follow-up, 36% (52/143) of the patients with Crohn’s disease, 24% (49/201) with ulcerative colitis and 4% (1/24) with IBD-U experienced an aggressive disease course. Future plans: We have established an inception cohort enabling ongoing initiatives to collect and generate clinical data and multi-omics datasets. The cohort will allow analyses for translation into candidate biosignatures to support clinical decision-making in IBD. Additionally, the data will provide insights into mechanisms of disease pathogenesis. Bullet points on strengths and weaknesses: This large, multicentre inception cohort of newly diagnosed adult IBD patients, with integrated biobanking and prospective material collection, enables exploration of IBD pathophysiology and biomarker discovery. The inclusion of symptomatic controls with gastrointestinal symptoms mimicking IBD but without evidence of the diagnosis provides a realistic diagnostic setting and addresses limitations of many previous cohorts. The use of healthy controls as a second control group offers opportunities to gain insight into IBD pathogenesis. The non-population-based study design and the predominance of university hospitals in recruitment may limit the generalisability of findings. Suboptimal sample processing at some centres, including delays in serum centrifugation and transportation of faecal samples at ambient temperatures, may have affected the quality of some specific analyses, such as microbiota analyses.
Open AccessCohort profile: The Swedish Inception Cohort in inflammatory bowel disease (SIC-IBD)
Purpose: There is a need for diagnostic and prognostic biosignatures to improve long-term outcomes in inflammatory bowel disease (IBD). Here, we describe the establishment of the Swedish inception cohort in IBD (SIC-IBD) and demonstrate its potential for the identification of such signatures. Participants: Patients aged ≥18 years with gastrointestinal symptoms who were referred to the gastroenterology unit due to suspected IBD at eight Swedish hospitals between November 2011 and March 2021 were eligible for inclusion. Findings to date: In total, 368 patients with IBD (Crohn’s disease, n=143; ulcerative colitis, n=201; IBD-unclassified, n=24) and 168 symptomatic controls were included. In addition, 59 healthy controls without gastrointestinal symptoms were recruited as a second control group. Biospecimens and clinical data were collected at inclusion and in patients with IBD also during follow-up to 10 years. Levels of faecal calprotectin and high-sensitivity C-reactive protein were higher in patients with IBD compared to symptomatic controls and healthy controls. Preliminary results highlight the potential of serum protein signatures and autoantibodies, as well as results from faecal markers, to differentiate between IBD and symptomatic controls in the cohort. During the first year of follow-up, 36% (52/143) of the patients with Crohn’s disease, 24% (49/201) with ulcerative colitis and 4% (1/24) with IBD-U experienced an aggressive disease course. Future plans: We have established an inception cohort enabling ongoing initiatives to collect and generate clinical data and multi-omics datasets. The cohort will allow analyses for translation into candidate biosignatures to support clinical decision-making in IBD. Additionally, the data will provide insights into mechanisms of disease pathogenesis. Bullet points on strengths and weaknesses: This large, multicentre inception cohort of newly diagnosed adult IBD patients, with integrated biobanking and prospective material collection, enables exploration of IBD pathophysiology and biomarker discovery. The inclusion of symptomatic controls with gastrointestinal symptoms mimicking IBD but without evidence of the diagnosis provides a realistic diagnostic setting and addresses limitations of many previous cohorts. The use of healthy controls as a second control group offers opportunities to gain insight into IBD pathogenesis. The non-population-based study design and the predominance of university hospitals in recruitment may limit the generalisability of findings. Suboptimal sample processing at some centres, including delays in serum centrifugation and transportation of faecal samples at ambient temperatures, may have affected the quality of some specific analyses, such as microbiota analyses.
- Open Access
- 4 November 2024
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (5)
Characterization of Inflammatory Bowel Disease Heterogeneity Using Serum Proteomics: A Multicenter Study
Background: Recent genetic and transcriptomic data highlight the need for improved molecular characterization of inflammatory bowel disease (IBD). Proteomics may advance the delineation of IBD phenotypes since it accounts for post-transcriptional modifications. Aims: We aimed to assess the IBD spectrum based on inflammatory serum proteins and identify discriminative patterns of underlying biological subtypes across multiple European cohorts. Methods: Using proximity extension methodology, we measured 86 inflammation-related serum proteins in 1551 IBD patients and 312 healthy controls (HC). We screened for proteins exhibiting significantly different levels among IBD subtypes and between IBD and HC. Classification models for differentiating between Crohn’s disease (CD) and ulcerative colitis (UC) were employed to explore the IBD spectrum based on estimated probability scores. Results: Levels of multiple proteins, such as interleukin-17A, matrix metalloproteinase-10, and fibroblast growth factor-19, differed (fold-change >1.2; false discovery rate 0.73) than colonic CD (median AUCs < 0.62). Models differentiating colonic CD from ileal CD demonstrated intermediate performance (median AUCs: 0.67–0.69). Conclusions: Our findings in serum proteins support the presence of a continuous IBD spectrum rather than a clear separation of CD and UC. Within the spectrum, disease location may reflect a more similar disease than CD versus UC, as colonic CD resembled UC more closely than ileal CD.
- 4 November 2024
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (5)
Open AccessCharacterization of Inflammatory Bowel Disease Heterogeneity Using Serum Proteomics: A Multicenter Study
Background: Recent genetic and transcriptomic data highlight the need for improved molecular characterization of inflammatory bowel disease (IBD). Proteomics may advance the delineation of IBD phenotypes since it accounts for post-transcriptional modifications. Aims: We aimed to assess the IBD spectrum based on inflammatory serum proteins and identify discriminative patterns of underlying biological subtypes across multiple European cohorts. Methods: Using proximity extension methodology, we measured 86 inflammation-related serum proteins in 1551 IBD patients and 312 healthy controls (HC). We screened for proteins exhibiting significantly different levels among IBD subtypes and between IBD and HC. Classification models for differentiating between Crohn’s disease (CD) and ulcerative colitis (UC) were employed to explore the IBD spectrum based on estimated probability scores. Results: Levels of multiple proteins, such as interleukin-17A, matrix metalloproteinase-10, and fibroblast growth factor-19, differed (fold-change >1.2; false discovery rate 0.73) than colonic CD (median AUCs < 0.62). Models differentiating colonic CD from ileal CD demonstrated intermediate performance (median AUCs: 0.67–0.69). Conclusions: Our findings in serum proteins support the presence of a continuous IBD spectrum rather than a clear separation of CD and UC. Within the spectrum, disease location may reflect a more similar disease than CD versus UC, as colonic CD resembled UC more closely than ileal CD.